According to various reports, the FDA's neuroscience expert Billy Dunn is leaving the agency after more than 15 years, effective immediately.
Dunn presided over the controversial approval of Biogen Inc's (NASDAQ: BIIB) Alzheimer's disease treatment, Aduhelm (aducanumab).
Dunn, 53, is retiring from the agency to "explore other opportunities," according to an internal FDA email. Dunn notified agency officials Friday, according to a person with knowledge of the situation.
The FDA has already postponed the application after the company submitted additional data.
Friedreich ataxia is a rare inherited disease that causes progressive damage to your nervous system and movement problems.
Nerve fibers in your spinal cord and peripheral nerves degenerate, becoming thinner.
Price Action: RETA shares are down 35.7% at $28.61 on the last check Monday.
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
This article Why Reata Pharmaceuticals Shares Are Falling Monday? originally appeared on Benzinga.com
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.